Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GREEN MEMORY phase 3 trial of sodium oligomannate in mild to moderate Alzheimer's disease
2020-001755-41Phase 3Completed
- Sponsor
- Green Valley
- Start
- Nov 2020
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Sodium oligomannate with Placebo (2 arms). Primary endpoint: Change from baseline to end of double-blind study in ADAS-Cog/11 score. Started Nov 2020; status: completed.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2020-001755-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001755-41.